eamdacademy.org-tbzV-1794392262-p720200356 1794392262 Eurasian Academy of Medicine and Dentistry info@eamdacademy.org Eurasian Academy of Medicine and Dentistry Journal of Applied Pharmaceutical Technologies and Systems J Appl Pharm Technol Syst 3149-9589 2025 4 1 Oliver Grant David Clark Sophia Nguyen 2025 10.68159/p720200356 https://eamdacademy.org/pub/journal/3/article/p720200356 Nkanga CI, Fisch A, Rad-Malekshahi M, Romic MD, Kittel B, Ullrich T, et al. Clinically established biodegradable long acting injectables: an industry perspective. Adv Drug Deliv Rev. 2020;167:19-46. Jindal AB, Bhide AR, Salave S, Rana D, Benival D. Long-acting parenteral drug delivery systems for the treatment of chronic diseases. Adv Drug Deliv Rev. 2023;198:114862. Vora LK, Sabri AH, Naser Y, Himawan A, Hutton AR, Anjani QK, et al. Long-acting microneedle formulations. Adv Drug Deliv Rev. 2023;201:115055. Alidori S, Subramanian R, Holm R. Patient-centric long-acting injectable and implantable platforms─ an industrial perspective. Mol Pharm. 2024 ;21(9):4238-58. Li L, Gatto GJ, Brand RM, Krovi SA, Cottrell ML, Norton C, van der Straten A, Johnson LM. Long-acting biodegradable implant for sustained delivery of antiretrovirals (ARVs) and hormones. JCR. 2021;340:188-99. Pons-Faudoa FP, Di Trani N, Capuani S, Campa-Carranza JN, Nehete B, Sharma S, et al. Long-acting refillable nanofluidic implant confers protection against SHIV infection in nonhuman primates. Sci Transl Med. 2023;15(702):eadg2887. Chua CY, Jain P, Ballerini A, Bruno G, Hood RL, Gupte M, et al. Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis. JCR. 2018;286:315-25. Benhabbour SR, Kovarova M, Jones C, Copeland DJ, Shrivastava R, Swanson MD, et al. Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery. Nat Commun. 2019;10(1):4324. Nakmode DD, Singh B, Abdella S, Song Y, Garg S. Long-acting parenteral formulations of hydrophilic drugs, proteins, and peptide therapeutics: mechanisms, challenges, and therapeutic benefits with a focus on technologies. DDTR. 2025;15(4):1156-80. Edagwa B, McMillan J, Sillman B, Gendelman HE. Long-acting slow effective release antiretroviral therapy. Expert Opin Drug Deliv. 2017;14(11):1281-91. Nayan MU, Sillman B, Hasan M, Deodhar S, Das S, Sultana A, et al. Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection. Adv Drug Deliv Rev. 2023;200:115009. Nayan MU, Panja S, Sultana A, Zaman LA, Vora LK, Sillman B, et al. Polymer delivery systems for long-acting antiretroviral drugs. Pharm. 2024;16(2):183. Donnelly RF, Larrañeta E. Microarray patches: potentially useful delivery systems for long-acting nanosuspensions. Drug Discov Today. 2018;23(5):1026-33. Markowicz-Piasecka M, Kubisiak M, Asendrych-Wicik K, Kołodziejczyk M, Grzelińska J, Fabijańska M, et al. Long-acting injectable antipsychotics—a review on formulation and in vitro dissolution. Pharm. 2023;16(1):28. Baryakova TH, Pogostin BH, Langer R, McHugh KJ. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nat Rev Drug Discov. 2023;22(5):387-409. Muddineti OS, Omri A. Current trends in PLGA based long-acting injectable products: The industry perspective. Expert Opin Drug Deliv. 2022;19(5):559-76. Bao Q, Wang X, Zou Y, Wang Y, Burgess DJ. In vitro release testing method development for long-acting injectable suspensions. Int J Pharm. 2022;622:121840. Bao Q, Wang X, Wan B, Zou Y, Wang Y, Burgess DJ. Development of in vitro-in vivo correlations for long-acting injectable suspensions. Int J Pharm. 2023;634:122642. Siemons M, Schroyen B, Darville N, Goyal N. Role of modeling and simulation in preclinical and clinical long-acting injectable drug development. The AAPS Journal. 2023;25(6):99. Shah JC, Hong J. Model for long acting injectables (depot formulation) based on pharmacokinetics and physical chemical properties. The AAPS Journal. 2022;24(3):44. Sharan S, Fang L, Lukacova V, Chen X, Hooker AC, Karlsson MO. Model‐Informed Drug Development for Long‐Acting Injectable Products: Summary of American College of Clinical Pharmacology Symposium. CPDD. 2021;10(3). Zou H, Banerjee P, Leung SS, Yan X. Application of pharmacokinetic-pharmacodynamic modeling in drug delivery: development and challenges. Front pharmacol. 2020;11:997. Park H, Otte A, Park K. Evolution of drug delivery systems: From 1950 to 2020 and beyond. JCR. 2022;342:53-65. Cao S, Liu Y, Shang H, Li S, Jiang J, Zhu X, Zhang P, Wang X, Li J. Supramolecular nanoparticles of calcitonin and dipeptide for long-term controlled release. JCR. 2017;256:182-92. Wang P, Zhuo X, Chu W, Tang X. Exenatide-loaded microsphere/thermosensitive hydrogel long-acting delivery system with high drug bioactivity. Int J Pharm. 2017;528(1-2):62-75. Jucker BM, Alsaid H, Rambo M, Lenhard SC, Hoang B, Xie F, et al. Multimodal imaging approach to examine biodistribution kinetics of Cabotegravir (GSK1265744) long acting parenteral formulation in rat. JCR. 2017;268:102-12. Bhat BB, Mehta CH, Suresh A, Velagacherla V, Nayak UY. Controlled release technologies for chronotherapy: current status and future perspectives. Curr Pharm Des. 2023;29(14):1069-91. Arroyo-Currás N, Ortega G, Copp DA, Ploense KL, Plaxco ZA, Kippin TE, et al. High-precision control of plasma drug levels using feedback-controlled dosing. ACS Pharmacol Transl Sci. 2018;1(2):110-8. Nieto K, Pei P, Wang D, Mallery SR, Schwendeman SP. In vivo controlled release of fenretinide from long-acting release depots for chemoprevention of oral squamous cell carcinoma recurrence. Int J Pharm. 2018;538(1-2):48-56.